Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis – a case series

Lohse, 2020, Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group, J. Hepatol., 73, 1496, 10.1016/j.jhep.2020.07.023 Pape, 2022, Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group, J. Hepatol., 76, 841, 10.1016/j.jhep.2021.12.041 Czaja, 2022, Advancing biologic therapy for refractory autoimmune hepatitis, Dig Dis Sci., 67, 4979, 10.1007/s10620-021-07378-4 Lindor, 2019, Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases, Hepatology, 69, 394, 10.1002/hep.30145 2017, Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis, J. Hepatol., 67, 145, 10.1016/j.jhep.2017.03.022 Grigorian, 2015, Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis, Clin Res Hepatol Gastroenterol, 39, 296, 10.1016/j.clinre.2015.02.011 Ramos-Casals, 2012, Primary sjogren syndrome, BMJ, 344, 10.1136/bmj.e3821 Stefanski, 2017, The diagnosis and treatment of sjogren's syndrome, Dtsch Arztebl Int, 114, 354 Mavragani, 2014, Sjogren's syndrome, Annu. Rev. Pathol., 9, 273, 10.1146/annurev-pathol-012513-104728 Chalifoux, 2017, Extrahepatic manifestations of primary biliary cholangitis, Gut Liver, 11, 771, 10.5009/gnl16365 Arvaniti, 2019, Epigenetic modifications in generalized autoimmune epithelitis: sjogren's syndrome and primary biliary cholangitis, Epigenomes, 3, 10.3390/epigenomes3030015 Selmi, 2017, Chronic autoimmune epithelitis in sjogren's syndrome and primary biliary cholangitis: a comprehensive review, Rheumatol Ther, 4, 263, 10.1007/s40744-017-0074-2 Lied, 2011, Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review, Scand. J. Immunol., 73, 1, 10.1111/j.1365-3083.2010.02470.x Migita, 2007, Elevated serum BAFF levels in patients with autoimmune hepatitis, Hum. Immunol., 68, 586, 10.1016/j.humimm.2007.03.010 Migita, 2010, Serum BAFF and APRIL levels in patients with PBC, Clin. Immunol. (San Diego, CA, U. S.), 134, 217 Lavie, 2004, Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome, J. Pathol., 202, 496, 10.1002/path.1533 Nishikawa, 2016, B-cell activating factor belonging to the tumor necrosis factor family and interferon-gamma-inducible protein-10 in autoimmune hepatitis, Medicine (Baltim.), 95 Liu, 2011, BAFF inhibition: a new class of drugs for the treatment of autoimmunity, Exp. Cell Res., 317, 1270, 10.1016/j.yexcr.2011.02.005 Pontarini, 2015, Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome, Rheumatology, 54, 1429, 10.1093/rheumatology/kev005 Arvaniti, 2020, Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis, JHEP Rep, 2 De Vita, 2015, Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study, Rheumatology, 54, 2249 Ramos-Casals, 2020, EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies, Ann. Rheum. Dis., 79, 3, 10.1136/annrheumdis-2019-216114 2015, European association for the study of the L. EASL clinical practice guidelines: autoimmune hepatitis, J. Hepatol., 63, 971, 10.1016/j.jhep.2015.06.030 Shiboski, 2016, American College of Rheumatology/European League against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts, Ann. Rheum. Dis., 76, 9, 10.1136/annrheumdis-2016-210571 Kaegi, 2021, Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders, Allergy, 76, 2673, 10.1111/all.14704 Weiler-Normann, 2021, Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation, Curr. Opin. Gastroenterol., 37, 86, 10.1097/MOG.0000000000000701 van den Brand, 2019, Adverse events related to low dose corticosteroids in autoimmune hepatitis, Aliment. Pharmacol. Ther., 50, 1120, 10.1111/apt.15528 Wallace, 2019, Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus, Arthritis Rheumatol., 71, 1125, 10.1002/art.40861 Blair, 2018, Belimumab: a review in systemic lupus erythematosus, Drugs, 78, 355, 10.1007/s40265-018-0872-z Molinaro, 2017, Why doesn't primary biliary cholangitis respond to immunosuppressive medications?, Curr. Hepat. Rep., 16, 119, 10.1007/s11901-017-0345-y Terziroli Beretta-Piccoli, 2019, The challenges of primary biliary cholangitis: what is new and what needs to be done, J. Autoimmun., 105, 10.1016/j.jaut.2019.102328 Wise, 2019, The safety of belimumab for the treatment of systemic lupus erythematosus, Expet Opin. Drug Saf., 18, 1133, 10.1080/14740338.2019.1685978